Clinical Trial Update: Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capivasertib plus fulvestrant versus fulvestrant alone in primary high-risk invasive lobular breast cancer; recruitment ongoing with Ki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Lobular Carcinoma of the Breast

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: CCCA Assessed by Ki67 Drop Below <2.7% From Baseline | Phase 2 | Status: RECRUITING